Ibrutinib 伊布鲁替尼

CAS 936563-96-1 MFCD036563961

化学结构图

936563-96-1
SMILES: C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1

化学属性

Mol. Weight440.49706
Appearance white solid powder
SolubilitySoluble in DMSO at 80 mg / mL, not in water

别名和识别编码

Chemical Name Translation伊布鲁替尼
Chemical NameIbrutinib
FormulaC25H24N6O2
Synonym PCI32765, PCI-32765, PCI 32765, Ibrutinib, Imbruvica
IUPAC Name(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.
InChIKeyXYFPWWZEPKGCCK-GOSISDBHSA-N
InChIInChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1
Canonical SMILESC=CC(N1C[C@H](N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C5=C(N)N=CN=C52)CCC1)=O
信息真实价格透明    资金保障    专业采购外包团队在线服务   
信息真实价格透明    资金保障    专业采购外包团队在线服务   
品牌质保精细包装    现货库存    一流品牌服务   

产品应用

  • Ibrutinib, also known as PCI-32765, is a potent and orally active BTK inhibitor. Ibrutinib binds to and inhibits BTK activity, preventing B-cell activation and B-cell-mediated signaling and inhibiting the growth of malignant B cells that overexpress BTK. Ibrutinib was approved by the US FDA on November 13, 2013 for the treatment of mantle cell lymphoma.

安全信息

Storage condition Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

系列性分类

  1. Medical Research Areas
  2. Angiogenesis
  3. BTK
  1. Medical Research Areas
  2. Angiogenesis
  3. Src

相关产品推荐